retinoic acid syndrome

(redirected from APL differentiation syndrome)

retinoic acid syndrome

complex of symptoms in patients taking all-trans retinoic acid for acute promyelocytic leukemia; comprises fever, dyspnea, weight gain, pulmonary infiltrates, pleural or pericardial effusions, episodic hypotension, renal dysfunction, and leukocytosis.

retinoic acid syndrome

A potentially fatal complication of all-trans retinoic acid (ATRA, tretinoin) therapy, which is seen in patients with acute promyelocytic leukemia, and characterised by fever, dyspnoea, weight gain, pulmonary infiltrates and pleural or pericardial effusions, ± leukocytosis.

Management
High-dose steroids (dexamethasone) begun at first signs of retinoic acid syndrome (e.g., unexplained fever, dyspnoea, weight gain, abnormal chest auscultatory findings or radiographic changes), irrespective of leukocyte count, continued for 3+ days until signs and symptoms have abated.
References in periodicals archive ?
Some patients with APL treated with TRISENOX have experienced APL differentiation syndrome -- with symptoms similar to retinoic acid-acute promyelocytic leukemia (RA-APL) syndrome.
We believe that the combination of tamibarotene and arsenic trioxide (ATO) could produce a complete response rate similar to the ATRA and ATO combination with fewer toxicities such as APL differentiation syndrome.
This patient reportedly had a severe toxic reaction called APL differentiation syndrome when given ATRA.
Some patients with APL treated with TRISENOX have experienced APL differentiation syndrome - with symptoms similar to retinoic acid-acute promyelocytic leukemia (RA-APL) syndrome.
We hypothesize that the combination of tamibarotene and arsenic trioxide will result in a similar complete response rate as the ATRA and arsenic trioxide combination, but with decreased toxicities, such as hyperleukocytosis, APL differentiation syndrome and rash and potentially a lower relapse rate," said Jessica K.
Those events attributable to TRISENOX in the phase 2 study of 40 patients with refractory or relapsed APL included QTc interval prolongation (n=16), APL differentiation syndrome (n=3), hyperleukocytosis (n=3), atrial dysrhythmias (n=2), hyperglycemia (n=2), and torsade de pointes (n=1).
Some patients with acute promyelocytic leukemia (APL) treated with TRISENOX(R) have experienced APL differentiation syndrome -- with symptoms similar to retinoic acid-acute promyelocytic leukemia (RA-APL) syndrome.
Some patients with acute promyelocytic leukemia (APL) treated with TRISENOX(R) have experienced APL differentiation syndrome - with symptoms similar to retinoic acid-acute promyelocytic leukemia (RA-APL) syndrome.